Back to top

oncology-screening: Archive

Zacks Equity Research

Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal

SYRS stock plummets as late-stage cancer study of lead candidate fails to achieve its primary endpoint leading to the termination of the study.

BIIBNegative Net Change ABBVPositive Net Change ALLOPositive Net Change